NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free MESO Stock Alerts $5.01 +1.52 (+43.55%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.91▼$5.3750-Day Range$1.76▼$5.0152-Week Range$1.61▼$10.24Volume14.03 million shsAverage Volume4.65 million shsMarket Capitalization$508.67 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside172.8% Upside$13.67 Price TargetShort InterestHealthy0.79% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.02 out of 5 starsMedical Sector615th out of 938 stocksBiological Products, Except Diagnostic Industry98th out of 148 stocks 3.1 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, Mesoblast has a forecasted upside of 172.8% from its current price of $5.01.Amount of Analyst CoverageMesoblast has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.79% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently increased by 59.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 2.4 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Mesoblast this week, compared to 2 articles on an average week.Search Interest22 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 2,100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesMarch 28, 2024 | morningstar.comMesoblast Ltd LWBMarch 27, 2024 | afr.comASX retreats ahead of CPI; Mesoblast soars 45pcMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 27, 2024 | msn.comiBio, ImmunityBio, Mesoblast among healthcare moversMarch 26, 2024 | msn.comFDA Commentary Sends Biotech Soaring During Premarket HoursMarch 26, 2024 | marketwatch.comMesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L ApplicationMarch 26, 2024 | fool.com.auMesoblast share price rockets 36% on breaking FDA newsMarch 26, 2024 | afr.comASX slips as tech declines; Mesoblast soars 47pcMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | markets.businessinsider.comFDA Indicates Adequate Data For Mesoblast's Remestemcel-L BLA Submission In Children With SR-aGVHDMarch 25, 2024 | globenewswire.comUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)March 21, 2024 | americanbankingnews.comHead-To-Head Contrast: Mesoblast (NASDAQ:MESO) versus Relay Therapeutics (NASDAQ:RLAY)March 20, 2024 | finance.yahoo.comMESO Jan 2025 0.500 callMarch 19, 2024 | finance.yahoo.comMESO Oct 2024 2.000 callMarch 19, 2024 | finance.yahoo.comMESO Jul 2024 2.000 putMarch 13, 2024 | globenewswire.comMesoblast Successfully Completes Placement and Accelerated Entitlement OfferMarch 11, 2024 | msn.comWhy Is Cell Therapy Focused-Mesoblast Stock Trading Higher On Monday?March 11, 2024 | marketwatch.comMesoblast Stock Rises 21% After FDA FeedbackMarch 10, 2024 | fool.com.auWhy 4DMedical, Block, Judo, and Mesoblast shares are pushing higher todayMarch 10, 2024 | globenewswire.comUnited States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)March 7, 2024 | fool.com.auWhy Cettire, GQG, Mesoblast, and Nine Entertainment shares are falling todayMarch 3, 2024 | finance.yahoo.comMesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call TranscriptMarch 3, 2024 | finance.yahoo.comMesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call TranscriptMarch 2, 2024 | seekingalpha.comMesoblast Limited (MESO) Q2 2024 Earnings Call TranscriptFebruary 29, 2024 | seekingalpha.comMesoblast Limited 2024 Q2 - Results - Earnings Call PresentationFebruary 29, 2024 | finance.yahoo.comMesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 28, 2024 | fool.com.auMesoblast share price tumbles on US$32.5m half-year lossSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today3/29/2024Next Earnings (Estimated)4/01/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees83Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$34.00 Low Stock Price Target$3.00 Potential Upside/Downside+172.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,890,000.00 Net Margins-1,061.43% Pretax Margin-1,094.53% Return on Equity-16.32% Return on Assets-12.26% Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick Ratio1.95 Sales & Book Value Annual Sales$7.50 million Price / Sales67.82 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book0.81Miscellaneous Outstanding Shares101,530,000Free Float82,446,000Market Cap$508.67 million OptionableOptionable Beta3.44 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $741.19kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $627.54kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsAnavex Life SciencesNASDAQ:AVXLMeiraGTxNASDAQ:MGTXInvivydNASDAQ:IVVDLexeo TherapeuticsNASDAQ:LXEOTScan TherapeuticsNASDAQ:TCRXView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 3,500 shares on 2/15/2024Ownership: 0.000%Affinity Asset Advisors LLCSold 400,000 shares on 2/13/2024Ownership: 0.000%Simplex Trading LLCSold 2,600 shares on 2/2/2024Ownership: 0.000%Penbrook Management LLCSold 10,000 shares on 1/16/2024Ownership: 0.276%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks. What is Mesoblast's stock price target for 2024? 6 brokerages have issued 12-month price objectives for Mesoblast's stock. Their MESO share price targets range from $3.00 to $34.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 172.8% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts. How have MESO shares performed in 2024? Mesoblast's stock was trading at $2.20 on January 1st, 2024. Since then, MESO stock has increased by 127.7% and is now trading at $5.01. View the best growth stocks for 2024 here. Are investors shorting Mesoblast? Mesoblast saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 806,500 shares, an increase of 59.2% from the February 29th total of 506,600 shares. Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is currently 0.5 days. View Mesoblast's Short Interest. When is Mesoblast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our MESO earnings forecast. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) released its earnings results on Wednesday, August, 30th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2 million. Mesoblast had a negative net margin of 1,061.43% and a negative trailing twelve-month return on equity of 16.32%. When did Mesoblast's stock split? Mesoblast shares reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV). When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's stock is owned by many different retail and institutional investors. Top institutional shareholders include Penbrook Management LLC (0.28%), Citadel Advisors LLC (0.00%), Affinity Asset Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MESO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.